TRANS-AML-EU
| Patologia: | Acute Myeloid Leukaemia |
| Area Tematica: | Medicina Personalizzata |
| Data di Inizio Progetto: | 01/04/2026 |
| Data di Fine Progetto: | 01/04/2029 |
| Finanziamento: | € 408.400,00 |
| Partenariato | ASST Gran Ospedale Metropolitano di Niguarda University of Helsinki, Institute for Molecular Medicine Finland (FIMM) (Finlandia) University Hospital Düsseldorf (Germania) SciLifeLab, OnkPath, Karolinska Institutet (Svezia) Medical Faculty Heidelberg, Heidelberg University (Germania) Leukämie Lymphom Liga e.V. (Leukaemia Lymphoma League) (Germania) Vilnius University Hospital Santaros Klinikos (Lituania) |
Acute Myeloid Leukaemia (AML) is notoriously heterogeneous: Patients with shared pathogenic mutations can respond very differently to therapies. Most pharmacogenomic strategies remain mutation-centric, overlooking multiple, intersecting biological programs that modulate drug response.
TRANS-AML-EU proposes a hallmark-driven alternative grounded in four innovations:
1. Pan-European multi-omics resource of >1.000 AML cases that pair genomics, epigenomics, transcriptomics and proteomics with ex vivo and clinical drug-response data. A privacy-preserving, GDPR-compliant federated architecture permits cross-border analysis.
2. Data-Driven Hallmarks (DDHMs): Using unsupervised integrative modelling (MOFA+, variational auto-encoders), we extract latent, independent disease programs. Each patient is described by a vector of DDHMs, enabling multi-axis precision medicine.
3. Translational Tool Boxes (TTBs) distil actionable hallmarks into (i) a minimal biomarker assay, (ii) a validated prediction or stratification algorithm, and (iii) standard operating procedures for laboratory and bioinformatic implementation. TTBs convert complex multi -omics discoveries into point-of-care decisions to maximize efficacy, potentially inform dosage considerations, and minimize risks of non-response or specific adverse events.
4. Consortium-wide validation and ex vivo trial simulation. Retrospective outcome analyses and a prospective multicentric ex vivo “clinical trial in a dish” will benchmark TTB predictions against clinical responses, engaging new centres and patient groups in participatory research.
Impact. TRANS-AML-EU will shift AML therapy selection from “one mutation, one drug” toward hallmark-driven prescriptions that combine or sequence therapies according to each patient’s unique DDHM profile. The resulting open, federated infrastructure and TTB workflow will be transferable to other diseases, establishing a new standard for multi-omics pharmacogenomics.